Paramore Miriam J
Known title: PRESIDENT AND CSOCIK: 0001713156
Associated companies
Transaction History
| OPRX | ▲ Buy | Option Exercise | 3,558 | $27K | 12/2/2021 | View on chart |
| OPRX | ▼ Sell | Open Market | 3,558 | $219K | 12/2/2021 | View on chart |
| OPRX | ▲ Buy | Option Exercise | 15,000 | $113K | 11/2/2021 | View on chart |
| OPRX | ▼ Sell | Open Market | 15,000 | $1.4M | 11/2/2021 | View on chart |
| OPRX | ▲ Buy | Option Exercise | 15,000 | $113K | 10/4/2021 | View on chart |
| OPRX | ▼ Sell | Open Market | 15,000 | $1.3M | 10/4/2021 | View on chart |
| OPRX | ▲ Buy | Option Exercise | 15,000 | $113K | 9/2/2021 | View on chart |
| OPRX | ▼ Sell | Open Market | 15,000 | $1.0M | 9/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
OptimizeRx Expands Ad Reach via OpenPath Deal with The Trade Desk
OptimizeRx has announced a partnership with The Trade Desk that uses its OpenPath platform to add authenticated healthcare professional reach to the ad network. The deal is expected to broaden the company’s inventory and provide advertisers with more precise targeting in the healthcare space. This collaboration follows a series of moves to grow OptimizeRx’s presence in the digital advertising market.
OptimizeRx Expands Ad Reach via OpenPath Deal with The Trade Desk. OptimizeRx has announced a partnership with The Trade Desk that uses its OpenPath platform to add authenticated healthcare professional reach to the ad network. The deal is expected to broaden the company’s inventory and provide advertisers with more precise targeting in the healthcare space. This collaboration follows a series of moves to grow OptimizeRx’s presence in the digital advertising market.